1313365-95-5

Basic information

• Product Name: (trans-4-amino-cyclohexylmethyl)-(4-iodo-phenyl)-methyl-amine
• Synonyms: (trans-4-amino-cyclohexylmethyl)-(4-iodo-phenyl)-methyl-amine
• CAS NO: 1313365-95-5
• Molecular Weight: 344.239
• Mol File: 1313365-95-5.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: (trans-4-amino-cyclohexylmethyl)-(4-iodo-phenyl)-methyl-amine(CAS DataBase Reference)
• NIST Chemistry Reference: (trans-4-amino-cyclohexylmethyl)-(4-iodo-phenyl)-methyl-amine(1313365-95-5)
• EPA Substance Registry System: (trans-4-amino-cyclohexylmethyl)-(4-iodo-phenyl)-methyl-amine(1313365-95-5)

Safety Data

• Hazardous Substances Data: 1313365-95-5(Hazardous Substances Data)

Upstream product

• 181308-57-6 trans-(4-formyl-cyclohexyl)-carbamic acid tert-butyl ester 
• 1313365-58-0 {4-[(4-iodo-phenylamino)-methyl]-trans-cyclohexyl}-carbamic acid tert-butyl ester 
• 304873-80-1 (4-formyl-cyclohexyl)-carbamic acid tert-butyl ester 
• 540-37-4 p-aminoiodobenzene 
• 1313365-62-6 (4-{[(4-iodo-phenyl)-methyl-amino]-methyl}-trans-cyclohexyl)-carbamic acid tert-butyl ester 

Downstream Products

• 1313365-94-4 (4-{[(4-iodo-phenyl)-methyl-amino]-methyl}-trans-cyclohexylamino)-acetic acid methyl ester 
• 1313365-97-7 4-(4-{[(4-iodo-phenyl)-methyl-amino]-methyl}-trans-cyclohexyl)-1-methyl-piperazin-2-one 
• 1313365-98-8 [[2-(tert-butoxycarbonyl-methyl-amino)-ethyl]-(4-{[(4-iodo-phenyl)-methyl-amino]-methyl}-trans-cyclohexyl)-amino]-acetic acid methyl ester 
• 1313363-54-0 (S)-1-(4-chloro-phenyl)-7-isopropoxy-6-methoxy-2-(4-{methyl-[4-(4-methyl-3-oxo-piperazin-1-yl)-trans-cyclohexylmethyl]-amino}-phenyl)-1,4-dihydro-2H-isoquinolin-3-one 

Relevant articles and documents

Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors

(Figure Presented). As a result of our efforts to discover novel p53:MDM2 protein-protein interaction inhibitors useful for treating cancer, the potent and selective MDM2 inhibitor NVP-CGM097 (1) with an excellent in vivo profile was selected as a clinical candidate and is currently in phase 1 clinical development. This article provides an overview of the discovery of this new clinical p53:MDM2 inhibitor. The following aspects are addressed: mechanism of action, scientific rationale, binding mode, medicinal chemistry, pharmacokinetic and pharmacodynamic properties, and in vivo pharmacology/toxicology in preclinical species.